Gujarat Themis Biosyn: Successfully Closes ₹750 Crore QIP

• Gujarat Themis Biosyn Limited successfully raised ₹750 crore through a Qualified Institutions Placement of equity shares.
• The QIP involved the issuance of shares to qualified institutional buyers located outside the United States.
• Trilegal advised Gujarat Themis Biosyn on the transaction, with a team led by Partners Kaushik Mukherjee and Kanika Sachdeva.
• CMS INDUSLAW provided legal counsel to the placement agents, including Nuvama Wealth Management Limited, 360 ONE WAM Limited, and Saffron Capital Advisors Private Limited.
• Gujarat Themis Biosyn is a major Indian manufacturer of pharmaceutical intermediates with over four decades of industry experience.

This transaction serves as a significant precedent for capital raising via Qualified Institutions Placements in India, particularly within the dynamic pharmaceutical sector.

Gujarat Themis Biosyn Limited has successfully concluded a Qualified Institutions Placement (QIP), securing ₹750 crore in capital. This substantial equity offering involved the issuance of shares to qualified institutional buyers located outside the United States, marking a notable financial maneuver for the pharmaceutical company.

The capital infusion through this Gujarat Themis Biosyn ₹750 crore QIP is poised to support the company's strategic objectives and operational expansion. Such a placement underscores investor confidence in the firm's market position and future prospects within the competitive Indian pharmaceutical landscape.

This transaction exemplifies a key method for capital generation in India, known as a Qualified Institutions Placement, enabling companies to raise funds from sophisticated investors without the extensive regulatory requirements of a public offering. The successful completion highlights the robust nature of India's capital markets for established industry players.

The complex legal aspects of this significant capital raise were navigated by prominent law firms, demonstrating their specialized expertise in equity offerings. Trilegal provided comprehensive legal counsel to Gujarat Themis Biosyn throughout the QIP process, ensuring compliance and smooth execution for the issuing company.

Trilegal's advisory team for Gujarat Themis Biosyn was led by Kaushik Mukherjee and Kanika Sachdeva, both of whom are now Partners at CMS INDUSLAW. They were supported by a dedicated team of associates including Yash Chhikara, Vaishnavi Tiwari, Aroosh Tarwani, Vikhyaat Maheshwari, and Dhairya Gawde, alongside associate trainees Roshan Bali and Janhavi Deo Yadav, highlighting a collaborative effort in facilitating the offering.

Concurrently, CMS INDUSLAW advised the consortium of placement agents involved in the QIP. These agents included Nuvama Wealth Management Limited, 360 ONE WAM Limited, and Saffron Capital Advisors Private Limited. The involvement of CMS INDUSLAW QIP advisory services for these key intermediaries underscores the intricate legal coordination required for such large-scale institutional placements, particularly involving entities like Nuvama Wealth Management QIP facilitation.

Gujarat Themis Biosyn Limited holds a distinguished position in the Indian pharmaceutical sector, boasting over four decades of industry experience. The company is recognized as one of India’s largest manufacturers of pharmaceutical intermediates, a critical component in drug production.

As an integrated fermentation-based pharmaceutical company, Gujarat Themis Biosyn possesses extensive capabilities spanning the development, manufacture, and supply of fermentation-derived pharmaceutical intermediates and active pharmaceutical ingredients. This comprehensive operational scope solidifies its role as a vital contributor to the pharmaceutical supply chain.

This transaction serves as a significant precedent for capital raising via Qualified Institutions Placements in India, particularly within the dynamic pharmaceutical sector. It not only showcases the financial viability of established players but also highlights the demonstrated expertise of legal advisors like Trilegal and CMS INDUSLAW in orchestrating such complex equity offerings.

This transaction serves as a precedent for capital raising via Qualified Institutions Placements in India, particularly within the pharmaceutical sector, and highlights the demonstrated expertise of Trilegal and CMS INDUSLAW in advising on such complex equity offerings.

Source: Original reporting via Bar & Bench